CIPH Ciphergen Biosystems (MM)

Leading Researchers Discover Novel Biomarkers for the Early Diagnosis of Alzheimer's Disease Using Ciphergen's SELDI ProteinChip(R) Technology Ten Studies Featuring SELDI Results Will be Presented at the 9th International Conference on Alzheimer's Disease in Philadelphia FREMONT, Calif., July 16 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (NASDAQ:CIPH) announced today that ten studies involving its proprietary SELDI ProteinChip(R) Technology for various aspects of Alzheimer's Disease research will be presented at the 9th International Conference on Alzheimer's Disease (ICAD) in Philadelphia which runs from July 17-22. These studies have identified multiple biomarkers and biomarker patterns that may lead to improved early detection of Alzheimer's and may suggest new targets for therapeutic intervention. Among these presentations, Prof. Kaj Blennow, M.D., Ph.D. from the University of Gothenburg, Sweden will be presenting promising data from a recent study done in collaboration with Ciphergen's Diagnostics Division during his plenary lecture on July 22 on "Biomarker's in Alzheimer's Disease." "Ciphergen has made significant progress working with leading researchers to develop a potential multi-marker SELDI-based assay for the diagnosis of AD utilizing novel biomarkers," said Huw Davies, Ph.D., Manager of Ciphergen's European Biomarker Center(R) facility. For a full list of SELDI presentations at the ICAD conference, please visit http://www.abstractsonline.com/viewer/?mkey=%7BF38908E2-C78B-40E5-B4F4- 9817BF853BD1%7D and type in the search term SELDI. Ciphergen will be on-site at its corporate booth (#629) during ICAD to meet anyone interested in learning more about our programs or technology and to answer any questions. About Ciphergen Ciphergen's Diagnostics Division is dedicated to the discovery of protein biomarkers and panels of biomarkers and their development into protein molecular diagnostic tests that improve patient care; and to providing collaborative R&D services through its Biomarker Discovery Center(R) laboratories for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Ciphergen's Biosystems Division develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research, and process proteomics applications, as well as a broad range of bioseparations media for protein purification and large scale production. ProteinChip Systems enable protein discovery, characterization, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Additional information about Ciphergen can be found at http://www.ciphergen.com/. Safe Harbor Statement Note Regarding Forward-Looking Statements: For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding biomarkers and biomarker patterns that may lead to improved early detection of Alzeimer's and may suggest new targets for therapeutic intervention, the use of ProteinChip technology to discover useful protein biomarkers that can act as novel drug targets or disease markers, develop and commercialize clinical diagnostics that improve patient care, the ability to provide services that lead to improved toxicology assays and diagnostic assays, and statements regarding our Diagnostics Division. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the ProteinChip technology's ability to validate and/or develop protein biomarkers as novel drug targets, diagnostic or toxicology assays, and the Company's ability to successfully commercialize such tests. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-Q dated May 10, 2004 and amended May 20, 2004, for further information regarding these and other risks of the Company's business. NOTE: Ciphergen, ProteinChip, Biomarker Discovery Center and BioSepra are registered trademarks of Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers, Investor Relations of Ciphergen Biosystems, Inc., +1-510-505 2297. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers, Investor Relations of Ciphergen Biosystems, Inc., +1-510-505 2297 Web site: http://www.ciphergen.com/

Copyright